Hepatic Cell Interactions of PEGylated Iron Oxide Nanopartic
2026-04-23
This study systematically reveals how nanoparticle size and PEGylation modulate hepatic cellular uptake, challenging previous assumptions about liver clearance mechanisms. The findings clarify cell-type-specific nanoparticle interactions and offer concrete guidance for safer, more targeted nanomedicine design.
TRIM66 and Epigenetic Control of Monogenic Olfactory Recepto
2026-04-22
This study identifies TRIM66 as a pivotal epigenetic repressor dictating monogenic and monoallelic olfactory receptor (OR) gene expression in mouse olfactory sensory neurons. By uncovering the mechanisms through which TRIM66 ensures singular receptor expression and maintains sensory fidelity, the research provides a new foundation for the molecular understanding of sensory gene regulation and neural circuit function.
CCCP in Mitochondrial Research: Protocols, AI Biomarkers & P
2026-04-22
CCCP (carbonyl cyanide m-chlorophenyl hydrazine) stands as a cornerstone tool for mitochondrial proton gradient disruption, powering next-gen workflows from live-cell imaging to deep learning-enabled biomarker discovery. This article bridges hands-on protocol guidance with advanced AI-driven applications, offering troubleshooting insights and highlighting APExBIO’s high-purity CCCP for reproducible, translational research.
HPF (Hydroxyphenyl Fluorescein): Next-Level hROS Assay Preci
2026-04-21
Explore the scientific foundations and advanced applications of HPF (hydroxyphenyl fluorescein) for highly reactive oxygen species detection. This article reveals unique mechanistic insights and protocol strategies to empower oxidative stress research.
Bazedoxifene Inhibits IL-6/GP130 Signaling: Implications for
2026-04-21
Shi et al. (2024) review the emerging role of bazedoxifene as an inhibitor of the IL-6/GP130 pathway, a central axis in tumor proliferation and survival. Their analysis highlights bazedoxifene's promise in impeding cancer progression and potentiating other anticancer therapies, informing the design of future mechanistic and translational studies.
Maximizing Protein Integrity: Translational Insights on Prot
2026-04-20
This thought-leadership article explores the mechanistic and strategic imperatives for robust protease inhibition in translational research. Building on new findings in ceramide-mediated mitochondrial injury and leveraging best practices in protein extraction, it provides actionable guidance for selecting and utilizing advanced solutions such as the Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) from APExBIO. The article differentiates itself by connecting molecular stress pathways, experimental protocols, and the competitive landscape, offering a vision for reproducible, clinically relevant discoveries.
iPSC-Based Clinical Trial Selection for Ultrarare Diseases
2026-04-20
This study introduces a patient-specific iPSC platform to prescreen drug efficacy and safety for individuals with ultrarare genetic diseases, directly addressing the uncertainty in conventional clinical trial enrollment. The approach demonstrates how personalized cellular models can refine treatment selection and advance precision medicine for rare metabolic disorders.
Cl-Amidine trifluoroacetate salt: Precision PAD4 Inhibition
2026-04-19
Cl-Amidine (trifluoroacetate salt) stands out as a selective PAD4 inhibitor, enabling researchers to dissect histone citrullination and immune regulation in cancer, autoimmunity, and septic shock models. Its robust performance in both in vitro and in vivo assays offers workflow advantages, especially where mechanistic specificity and reproducibility are paramount.
Prostaglandin E2: Optimizing Inflammation Research Workflows
2026-04-18
Prostaglandin E2 (PGE2) powers advanced inflammation research, immune regulation, and gastrointestinal protection studies with high receptor selectivity and reproducibility. This article delivers actionable protocol guidance and troubleshooting strategies to maximize data quality using APExBIO’s highly pure PGE2.
In Vivo Pharmacokinetics of RG108: Insights for DNMT Inhibit
2026-04-17
This study systematically examines the pharmacokinetics of RG108, a non-nucleosidic DNA methyltransferase inhibitor, after subcutaneous administration in rats. The findings highlight RG108’s favorable tissue distribution, safety profile, and suitability for in vivo epigenetic modulation, with implications for research beyond oncology.
3X (DYKDDDDK) Peptide: Raising the Bar for Translational Pro
2026-04-16
Explore how the 3X (DYKDDDDK) Peptide empowers translational researchers with advanced mechanistic insight and strategic guidance. This article uniquely integrates recent structural biology findings, including SPFH complexes, to demonstrate how the 3X FLAG peptide unlocks new dimensions in affinity purification, immunodetection, and protein crystallization. Discover how APExBIO’s offering sets a new standard for reproducibility, sensitivity, and workflow adaptability—bridging the gap between biological discovery and clinical innovation.
POx-Lipid Nanoparticles: A PEG-Free Platform for mRNA Delive
2026-04-15
This study introduces poly(2-ethyl-2-oxazoline) (POx) lipids as alternatives to PEG-lipids in lipid nanoparticle (LNP) formulations for mRNA delivery. The work demonstrates that POx-lipids enable efficient mRNA encapsulation, mitigate immune reactivity associated with PEG, and maintain or enhance transfection efficiency, providing valuable insight for next-generation gene delivery systems.
THBS1 as a Prognostic and Therapeutic Target in Laryngeal Ca
2026-04-14
This study applies integrative bioinformatics and in vitro validation to identify THBS1 as both a prognostic biomarker and a potential therapeutic vulnerability in laryngeal cancer. The findings highlight altered lipid metabolism among key pathways in tumor progression and provide analytic and experimental evidence for THBS1’s role in shaping the tumor microenvironment and patient outcomes.
RWJ 67657: Precision p38 MAPK Inhibition in Cytokine Researc
2026-04-13
RWJ 67657 (JNJ-3026582) elevates inflammatory disease research by combining potent, isoform-selective p38 MAP kinase blockade with an innovative mechanism that enhances dephosphorylation of p38α. This dual-action profile enables researchers to dissect cytokine regulation with unprecedented specificity and reliability.
Kaixin Jieyu Granule Modulates PI3K/Akt Pathway in Depressio
2026-04-12
Xu et al. (2023) systematically demonstrate that Kaixin Jieyu Granule (KJG) alleviates neuroinflammation-induced depressive-like behaviors in mice by targeting the TLR4/PI3K/AKT/FOXO1 signaling axis. Their combined network pharmacology and experimental approach clarifies the molecular mechanisms of KJG, providing a robust framework for future therapeutic research on depression and neuroinflammation.
457 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page